Plasmodium ovale Infection After One Year Mefloquine Prophylaxis in A Young Indonesian Soldier: A Case Report

Authors

  • Frans Liwang Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Dewi Mira Ratih Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Soroy Lardo Department of Internal Medicine, The Central Army Gatot Soebroto Hospital, Jakarta, Indonesia

Keywords:

plasmodium ovale, mefloquine, malaria prophylaxis, tertiana malaria

Abstract

Malaria chemoprevention using mefloquine has become the WHO standard regimen for military personnel who stay in the endemic area for an extended period of time. We reported a case of Plasmodium ovale infection in a young Indonesian Soldier following one year mefloquine prophylaxis 250 mg weekly. Typical fever and chills were experienced two weeks after returning from one year duty in Congo, West-Central Africa. The diagnosis of ovale malaria was made by peripheral blood smear, and 35/250 parasites in small microscopic view was found. Then, he recovered after dihydroartemisin and primaquine combination therapy. This was an unusual case of long-term prophylaxis failure since mefloquine has been recognized as the agent for malaria prevention, even multi-drug-resistance Plasmodium. Dormant stage of Plasmodium ovale, quinoline-resistance potential, and the efficacy of mefloquine itself are discussed as the cause of that phenomenon.

References

White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383(9918):723-35.

Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J. 2010;9:357.

Schlagenhauf P, Hatz C, Behrens R, et al. Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Travel Med Infect Dis. 2015;13(2):192-6.

Nevin RL, Pietrusiak PP, Caci JB. Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan. Malar J. 2008;7:30.

Nevin RL. Rational risk-benefit decision-making in the setting of military mefloquine policy. J Parasitol Res. 2015;2015:260106.

Liew JW, Mahmud R, Tan LH, Lau YL. Diagnosis of an imported Plasmodium ovale wallikeri infection in Malaysia. Malar J. 2016;15:8.

de Laval F, Oliver M, Rapp C, et al. The challenge of diagnosing Plasmodium ovale malaria in travellers: report of six clustered cases in French soldiers returning from West Africa. Malar J. 2010;9:358.

Alemu A, Fuehrer HP, Getnet G, Tessema B, Noedl H. Plasmodium ovale curtisi and Plasmodium ovale wallikeri in North-West Ethopia. Malar J. 2013;12:346.

Tomar LR, Giri S, Bauddh NK, Jhamb R. Complicated malaria: a rare presentation of Plasmodium ovale. Trop Doct. 2015;45(2):140-2.

Sonmez A, Harlak A, Kilic S, et al. The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan. J Infect. 2005;51(3):253-8.

Richter J, Franken G, Mehlhorn H, Labisch A, Haussinger D. What is the evidence for the existence of Plasmodium ovale hypnozoites? Parasitol Res. 2010;107(6):1285-90.

Richter J, Franken G, Holtfreter MC, Walter S, Labisch A, Mehlhorn H. Clinical implications of a gradual dormancy concept in malaria. Parasitol Res. 2016;115(6):2139-48.

Strydom KA, Ismail F, Frean J. Plasmodium ovale: a case of not-so-benign tertian malaria. Malar J. 2014;13:85.

Fuehrer HP, Noedl H. Recent advances in detection of Plasmodium ovale: implications of separation into the two species Plasmodium ovale wallikeri and Plasmodium ovale curtisi. J Clin Microbiol. 2014;52(2):387-91.

Lau YL, Lee WC, Tan LH, et al. Acute respiratory distress syndrome and acute renal failure from Plasmodium ovale infection with fatal outcome. Malar J. 2013;12(389).

Siswantoro H, Russell B, Ratcliff A, et al. In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother. 2011;55(1):197-202.

McCarthy S. Malaria prevention, mefloquine neurotoxicity, neuropsychiatric illness, and risk-benefit analysis in the Australian Defence Force. J Parasitol Res. 2015;2015:287651.

Gogtay NJ, Ferner RE. Mefloquine for malarial prophylaxis in military personnel. BMJ. 2015;351:h5797.

Amet S, Zimner-Rapuch S, Launay-Vacher V, Janus N, Deray G. Malaria prophylaxis in patients with renal impairment: a review. Drug Saf. 2013;36(2):83-91.

Lee EY, Maguire JH. Acute pulmonary edema complicating ovale malaria. Clin Infect Dis. 1999;29(3):697-8.

Downloads

Published

2019-05-10

How to Cite

Liwang, F., Ratih, D. M., & Lardo, S. (2019). Plasmodium ovale Infection After One Year Mefloquine Prophylaxis in A Young Indonesian Soldier: A Case Report. Acta Medica Indonesiana, 51(1), 59. Retrieved from https://actamedindones.org/index.php/ijim/article/view/237

Issue

Vol. 51 No. 1 (2019): Acta Medica Indonesiana

Section

CASE REPORT

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.